Vanguard health care ETF sees record trading as big pharma soars

A boom in major U.S. pharmaceutical stocks is creating a swarm of activity around an ETF tracking the massive drugmakers.

U.S. drugmakers are hot, with Pfizer, Eli Lilly and Merck soaring to 16-year highs after reporting stronger than expected second-quarter results.
Tablets are arranged for a photograph in Mumbai, India, Photographer: Dhiraj Singh/Bloomberg

The $8.2 billion Vanguard Health Care ETF (VHT) had 1.6 million shares worth $272 million trade Monday, record one-day turnover for the fund. It also hasn’t seen a day of outflows in August, with $14 million of net inflows putting the ETF on track for its best month since June 2017.

U.S. drugmakers are hot, with Pfizer, Eli Lilly and Merck soaring to 16-year highs after reporting stronger than expected second-quarter results and the S&P 500 pharmaceuticals industry group hitting an all-time high Monday. Together, Pfizer and Merck make up more than 10% of the fund’s exposure. Its largest holding is industry bellwether Johnson & Johnson, which is heading for its best four-day run since early 2016.

A smaller health care fund, BlackRock’s $850 million iShares U.S. Healthcare Providers ETF (IHF) saw $48 million of inflows Monday, the most in almost two months. Trading volume in the fund hit $54 million Monday, more than eight times its average over the past year.

Bloomberg News
ETFs Asset managers Fund performance Healthcare industry Vanguard Money Management Executive
MORE FROM FINANCIAL PLANNING